COVID-19
A New Routine
Everyone has been adjusting to COVID-19 life for a year and, during that time, Metabolon has found its new routine with a productive hybrid model. Our lab staff continues to impress with the level of care to the highest quality standards while protecting fellow team members against COVID-19. Since day one, we have taken extra precautions for the safety and well-being of our team. Once we were able, we prioritized getting our onsite lab staff access to vaccines as essential personnel moving science forward.
Recognized for our cutting-edge approach to metabolomics, Metabolon has been a valued resource for COVID-19 researchers worldwide. Our actionable metabolomic insights have fueled pivotal and high-profile studies like the National Institute of Allergy and Infectious Diseases (NIAID) IMPACC study research to improve understanding of high-risk patients. These and other metabolomics projects are helping get closer to the phenotype and pressing forward on COVID-19 answers. Institute for Systems Biology research to improve understanding of high-risk patients. These and other metabolomics projects are helping get closer to the phenotype and pressing forward on COVID-19 answers.

Supporting Decentralized Metabolomics Testing Location Needs
The scientific community has learned a lot this year. We know that your research has been faced with unprecedented circumstances due to the COVID pandemic, limiting the ability of patients to access the lab for the collection of blood plasma and serum. This dynamic has slowed or prevented many research programs globally. While there are now vaccine options, greater caution will surround us for some time. To continue to support your metabolomic research needs, including facilitating remote clinical trials, we have invested in alternative sampling methods to meet decentralized testing location needs.
We are eager to join you in the fight to stop this global health crisis. Please contact your Metabolon Sales Representative or email us at [email protected] to discuss your specific program needs.

Dried blood spot (DBS) cards
The ability to sample and ship small volumes of blood on a DBS card represents an alternative to in-clinic visits, allowing monitoring of vulnerable patients and testing of remote populations without escalating sampling costs. DBS cards allow sampling of small volumes with less invasive devices, providing an ideal solution for frequent collections such as for human longitudinal studies and animal pharmacokinetics and pharmacodynamic studies that require frequent collections – sometimes daily or even hourly.

OMNImet™·GUT
This in-home collection device for metabolomics study of fecal samples delivers needed flexibility for microbiome studies. The proprietary stabilization chemistry in the OMNImet·GUT device provides ambient-temperature stability that does not require immediate freezing and cumbersome and expensive cold-chain logistics. The design maintains the integrity of the sample for metabolomics analysis for multiple days at ambient temperature. The increased flexibility, ease of use, and lower shipping costs provided by OMNImet·GUT device can offer significant advantages to clinical trial recruitment and execution.
COVID-19 FAQ
What you need to know about how we are adjusting our business in response to the coronavirus (COVID19) to continue to meet the needs of our clients. If your question is not addressed here, please contact us at [email protected] for more information. (Updated 4/27/2021)
Case Studies
Understanding the pathophysiology and immune response of infectious diseases is vital for discovering effective treatments. These case studies support several problem-oriented metabolomics applications to SARS-CoV-2 by identifying metabolomic changes during infection and predicting disease severity and need for effective intervention and efficacy.
When dealing with a pandemic like COVID-19, vaccine development and discovery of therapeutics are essential to improving outcomes. These case studies address the need for actionable insights for vaccine development that metabolomics provides through a comprehensive view driving operational and quality improvements and antibody production.
Understanding the effects of age, gender and comorbidities on susceptibility to COVID-19, response to treatment and outcomes like mortality are vital for improved outcomes. These case studies highlight how metabolomics guides effective intervention and efficacy.
Comprehensive metabolomic profiling can simultaneously inform on several biological processes relevant to infection, such as inflammatory and redox markers, energetics, microbiome contribution and xenobiotic impact. These insights can lead to predictive response signatures and therapy strategies. The following case studies demonstrate how metabolomics enhances understanding of viral activity, helps to predict viral treatment and supports informed decisions on vaccine development.
Enlighten your research,
accelerate your discovery.
Contact Us
Talk with an expert
Request a quote for our services or more information on sample types and handling procedures, need a letter of support, or simply have questions about how metabolomics can advance your research.
617 Davis Drive, Suite 100
Morrisville, NC 27560
Mailing Address:
P.O. Box 110407
Research Triangle Park, NCÂ 27709
Metabolon GmbH
ZeppelinstraĂŸe 3
85399 Hallbergmoos
Germany